These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15704614)

  • 21. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical pharmacology: current status and perspectives].
    De Schaepdryver AF
    Verh K Acad Geneeskd Belg; 1992; 54(1):7-26. PubMed ID: 1636323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Importance of in vivo pharmacology in research and development].
    Barbier A
    Therapie; 2004; 59(1):45-50. PubMed ID: 15199667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Contribution of pharmacology for new drug application in Japan].
    Suzuki-Nishimura T; Toyoshima S; Uyama Y; Yamada H; Hosoki R; Fujimori K; Nagao T
    Nihon Yakurigaku Zasshi; 2002 Sep; 120(3):187-94. PubMed ID: 12271514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Historical sketch of modern pharmaceutical science and technology (Part 3). From the second half of the 19th century to World War II].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(1):1-10. PubMed ID: 11613518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry.
    Winther FO; Hole OP; Nitter-Hauge S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):909-12. PubMed ID: 17673994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Financial conflicts of interest in science.
    Sax JK
    Ann Health Law; 2012; 21(2):291-327, 6 p preceding i. PubMed ID: 22606918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Merck fellowships contribute to the continued growth of clinical pharmacology in Sweden.
    Sjöqvist F; Eriksson LO; Andersson KE
    Eur J Clin Pharmacol; 2007 Mar; 63(3):229-31. PubMed ID: 17235553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?
    Land WG; Gutmann T; Daar AS
    Acta Chir Belg; 2008; 108(1):73-82. PubMed ID: 18411578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Academic medical centers and medical research: the challenges ahead.
    Cohen JJ; Siegel EK
    JAMA; 2005 Sep; 294(11):1367-72. PubMed ID: 16174695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The changing roles of industry and academia.
    Bauer EA; Cohen DE
    J Invest Dermatol; 2012 Mar; 132(3 Pt 2):1033-6. PubMed ID: 22330271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Training research scientists for drug discovery].
    Cros J
    Ann Pharm Fr; 2000 Jul; 58(4):228-31. PubMed ID: 10915969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commentary: a ray of hope for medical school research funding.
    Gabbe SG; Lockwood CJ; Marsh CB
    Acad Med; 2012 Nov; 87(11):1464-5. PubMed ID: 23111257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall?
    Tierney WM; Meslin EM; Kroenke K
    J Gen Intern Med; 2016 Feb; 31(2):228-233. PubMed ID: 26307387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The drug industry and clinical research in interwar America: three types of physician collaborator.
    Rasmussen N
    Bull Hist Med; 2005; 79(1):50-80. PubMed ID: 15764827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.